Consolidate healthcare data sets from multiple sources and utilize a single source of truth for improved decision making throughout the drug life cycle.
Life sciences organizations have a pressing need for real-world evidence across the value chain to improve decision making and deliver patient- centric strategies that lead to better health outcomes. However, organizations are challenged with gathering actionable insights at the speed needed to effectively bring innovation and new therapies to life.
DXC Open Health Connect for Life Sciences consolidates healthcare datasets from multiple sources and enables customers to utilize a single source of truth for their accurate decision making throughout the drug development life cycle. The resulting information attained through a personalized patient experience approach and a unified data platform helps life sciences companies bring new, targeted and effective treatments to market faster.
Supporting healthcare and life sciences convergence
With DXC Open Health Connect for Life Sciences, the life sciences value chain and the healthcare ecosystem can converge, enabling customers to derive actionable, evidence-based insights that deliver value in personalized, innovative ways.
The platform provides life sciences companies with the speed, scale and flexibility needed to securely gather key insights to accelerate the decision-making process for discovering new treatments or medicines.
DXC can help you embrace a patient- centered strategy through the lens of a customized collaboration platform that enables multiple facilities to securely update patient files in real time, inside or outside of the hospital.
DXC Open Health Connect for Life Sciences creates insights that enable life sciences organizations to process patient data quickly while validating specific use cases that span the life sciences spectrum of research and discovery, preclinical and clinical development, regulatory and market access, and commercialization.
These various datasets are integrated under common data models such as the Fast Healthcare Interoperability Resources (FHIR) and the Observational Medical Outcomes Partnership (OMOP).
DXC Open Health Connect for Life Sciences capabilities
The capabilities can be expanded based on specific needs. The platform is a three-tier architecture system for closed-loop intelligence:
- Systems of record support the integration of multiple data sources across life sciences and healthcare.
- Systems of insight enable data to be ingested, linked and standardized in a common model based on FHIR standards to the main life sciences data models (OMOP for research, Clinical Data Interchange Standards Consortium [CDISC] for regulatory), which will provide curated and usable data for research, patient engagement and clinical trials. The data can also be enriched through machine learning and AI algorithms.
- Systems of engagement enable users to rapidly deploy applications leveraging standard and smart data using an API, gaining actionable insights by using these apps as “digital front doors” for users.
Business platforms for life sciences
DXC Open Health Connect for Life Sciences delivers a specific business platform that meets the challenges of today’s life sciences landscape:
- Patient engagement
- Research and discovery
- Intelligent clinical trials
- Real-world insights network
- Regulatory intelligence
- Market access
- Intelligent commercialization
- Pharmacovigilance
Transforming and accelerating progress
The business applications in DXC Open Health Connect for Life Sciences span the drug production life cycle, creating actionable insights that let companies achieve their targets and objectives in many different scenarios, such as:
- Provide a single repository with standardized clinical trial data and DXC’s solution that can carry out inquiries across multiple trials in different therapeutic areas and indications. The platform helps pharma companies extract
- information for research purposes and quickly manage patient consent.
- Leverage advanced large healthcare datasets with predictive analytic models. Life sciences companies can locate previously diagnosed, lapsed and undiagnosed patients as well as the physicians that treated them.
- Analyze in-depth data from electronic health records, pharmacy dispensation data and internal
- product data. Life sciences companies can attain real-world evidence to support regulatory decisions, such as label extensions.
Why DXC
- Realize rapid value. Quickly aggregate data and creates an open, interoperable, agile environment — connecting assets that often exist in silos.
- Connect disparate data sources. DXC’s expertise allows users to create an integrated digital record and/or a consolidated data lake that links information across networks in a consistent and standardized way.
- Patient data privacy. DXC’s solutions are patient-centered. Consent management allows patients to set their preferences for data sharing across the healthcare ecosystem while blockchain and smart contracts capabilities ensure traceability, immutability and transparency in terms of the use of the patient’s data.
- Industry experience. DXC has more than 30 years of industry-leading life sciences experience, and 50 years of healthcare experience. DXC provides expertise to approximately 400 customers in the pharma, biotech, genetics, medical distribution and medical device sectors.
- Optimal flexibility. DXC’s nonproprietary installation supports cloud, on-premises and hybrid deployments based on the customer’s needs, enabling them to scale the solution up and down with ease.